Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. (Q30369026)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

Deborah L. Birx

6

object named as

Deborah L Birx

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Francine E McCutchan

8

object named as

Francine E McCutchan

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Eric Sanders-Buell

3

object named as

Eric Sanders-Buell

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

5

object named as

Merlin L Robb

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

7

object named as

Nelson L Michael

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Victoria R Polonis

9

object named as

Victoria R Polonis

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Lindsay Wieczorek

2

object named as

Lindsay Wieczorek

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Bruce K Brown

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Andrew Rosa Borges

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

22 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

375

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

529-538

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Determining neutralization serotypes of HIV type 1 by neural networks

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Diversity of the human immunodeficiency virus type 1 envelope glycoprotein in San Francisco Men's Health Study participants

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

HIV vaccine strategies

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Quantitative infectivity assay for HIV-1 and-2.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Bioorganic approaches towards HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Mechanisms contributing to the neutralization of HIV-1.

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016/J.VIROL.2008.02.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2008.02.022

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30369026&oldid=1755125702"